Webb, Erin; Richardson, Erica; Vogler, Sabine; Panteli, Dimitra (2022): What are the implications of policies increasing transparency of prices paid for pharmaceuticals? World Health Organization. Regional Office for Europe, Copenhagen.

Full text not available from this repository.


Policy action on net price transparency (NPT) for pharmaceuticals – the public disclosure of prices paid to manufacturers – is not straightforward:
(-) empirical evidence on its effect is extremely limited
(-) some stakeholders are concerned that moves towards increased price transparency would have a negative impact on accessibility (-) payers in different health systems may consider measures to increase price transparency as more or less necessary to increase affordable access to medicines.
Any movement towards NPT requires a re-examination of the established trade-offs in pharmaceutical policy in Europe and worldwide. It is important to consider, for example:
(-) the differing needs and negotiating capacities across countries (-) the complexities of the interactions between stakeholders (-) the way the process of implementation may shape the policy’s impact (-) the possible implications for innovation. Increasing transparency in the pharmaceutical system will require greater European and international collaboration – strengthening and going beyond existing initiatives. It also demands a clear focus on maintaining access, innovation and sustainability. Recent experience with joint purchasing, such as in the case of the COVID-19 vaccines, may bolster similar initiatives in future.

Item Type: Monograph (Other)
Subjects: OEBIG > Pharmaoekonomie
Date Deposited: 28 Sep 2022 15:19
Last Modified: 28 Sep 2022 15:19
URI: https://jasmin.goeg.at/id/eprint/2319